Regulatory B cell
Regulatory B cells (Bregs or B reg cells) represent a small population of B cells that participates in immunomodulation and in the suppression of immune responses.
≈ 5 min read
Regulatory B cell. encyclopegia.org, snapshot enwiki-001333003330. /a/regulatory-b-cell
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Regulatory B cells (Bregs or B reg cells) represent a small population of B cells that participates in immunomodulation and in the suppression of immune responses. The population of Bregs is highly heterogeneous and can be separated into different subsets such as B10 cells, memory B cells, transitional B cells, marginal zone B cells, Br1 cells, GrB + B cells, CD9 + B cells and even some plasmablasts or plasma cells, with reported phenotypic differences between subsets described in humans and mice.
Bregs regulate the immune system by different mechanisms. One of the main mechanisms is the production of anti-inflammatory cytokines such as interleukin 10 (IL-10), IL-35, or transforming growth factor beta (TGF-β).
Another known mechanism is the production of cytotoxic Granzyme B. Bregs also express various inhibitory surface markers such as programmed death-ligand 1 (PD-L1), CD39, CD73, and aryl hydrocarbon receptor. The regulatory effects of Bregs were described in various models of inflammation, autoimmune diseases, transplantation reactions, and in anti-tumor immunity.
History
The history of Breg research is can be described as progressing through four eras: early functional discovery (1960s–1990s), term coining and initial phenotypic characterization (2000s), mechanistic and therapeutic expansion (2010s), and the current omics-driven phase (2020s–onwards). In the 1960s-1970s it was noticed that B cells could suppress immune reaction beyond antibody production.
In 1996 Janeway's group observed an immunomodulation of experimental autoimmune encephalomyelitis (EAE) by B cells. Similar results were shown in a model of chronic colitis one year later. Then a role of Bregs was found in many mouse models of autoimmune diseases as rheumatoid arthritis or systemic lupus erythematosus (SLE).
Timeline of Breg journey. EAE, experimental autoimmune encephalomyelitis; GzmB, granzyme B; LARS2, leucine-tRNA-synthetase-2; PPARδ, peroxisome proliferator-activated receptor delta; Trx, thioredoxin.
Development and populations
Bregs can develop from different subsets of B cells such as immature and mature B cells or plasmablasts. Whether Breg cells uniquely derive from a specific progenitor or originate within conventional B cell subsets is still an open question.
Unfortunately, Breg cells are more difficult to define than regulatory T cells (Tregs) since they lack a lineage marker analogous to the Treg cell marker - FOXP3. Bregs share many markers with various B cell subsets due to their origin.
Human and murine Bregs can be further separated into many subsets due to their different mechanism of action and distinct expression of key surface markers (table below). It is estimated that IL-10 producing B cell subpopulations can constitute up to 10% of circulating human B cells. There is still no clear consensus on the classification and definition of Breg cells.
Mouse Bregs were mainly CD5 and CD1d positive in the model of EAE or after the exposition of Leishmania major. By contrast, mouse Bregs in model of collagen-induced arthritis (CIA) were mainly CD21 and CD23 positive. Bregs were found in humans, too.
Markers of peripheral blood Bregs were molecules CD24 and CD38. However, peripheral blood Bregs were mostly CD24 and CD27 positive after cultivation with anti-CD40 antibody and CpG bacterial DNA. They were also positive for CD25, CD71 and PD-L1 after stimulation by CpG bacterial DNA and through TLR9.
Mechanisms of action
There are several mechanisms of Breg action. Nevertheless, the most examined mechanism is the production of IL-10. IL-10 has strong anti-inflammatory effects.
It inhibits (or suppresses) inflammatory reactions mediated by T cells, especially Th1 and Th17 type immune reactions. This was shown for example in the models of EAE, CIA or contact hypersensitivity. Likewise, regulatory B cell subsets have also been demonstrated to inhibit Th1 responses through IL-10 production during chronic infectious diseases such as visceral leishmaniasis.
By production of IL-10, Bregs are also capable of conversion of naïve CD4 + T cells into Tregs and IL-10-secreting type 1 regulatory CD4 + T cells. This has been observed in various experimental models as well as chronically virus-infected patients. Another mechanism of Breg suppression is the production of transforming growth factor (TGF-β), an anti-inflammatory cytokine.
The role of Bregs producing TGF-β was found in the mouse models of SLE and diabetes. The last anti-inflammatory cytokine produced only by some Bregs is IL-35, which plays a role in Treg conversion. Breg cells are capable of releasing IL-35 containing exosomes.
It is not yet clear whether IL-10 and IL-35-producing Bregs correspond to separate populations or display some degree of overlap. Besides the production of immunomodulatory cytokines, Bregs also release cytotoxic granzyme B involved in the degradation of the T cell receptor and T cell apoptosis.
Another mechanism of Breg suppression involves surface molecules such as FasL, which induces T cell death, or PD-1 and PD-L1. PD-1 + Bregs have been shown to suppress CD4 + and CD8 + T cell activity and induce Tr1 cells, while PD-L1 Bregs were reported to inhibit NK and CD8 + T cell cytotoxicity.
Some Bregs also express additional suppressive molecules such as CD39, CD73, and aryl hydrocarbon receptor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1333003330 under CC BY-SA 4.0; modifications have been made.